SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and
technology company focused on unmet needs in viral diseases,
oncology and inflammation, today announced that the company will
participate in the virtual H.C. Wainwright BioConnect 2021
Conference to be held Jan. 11-14,
2021.
A webcast of Aethlon Medical's presentation will be available
on-demand as of 6:00 a.m. EDT,
Monday, Jan. 11, 2021. The webcast
can be accessed at
https://journey.ct.events/view/438e8db3-76ee-47fc-8af0-3270786018d9 and the
investor relations section of Aethlon Medical's website at
www.aethlonmedical.com.
About Aethlon and the Hemopurifier®
Aethlon is focused on addressing unmet needs in global health.
The Aethlon Hemopurifier is a clinical-stage immunotherapeutic
device designed to combat cancer and life-threatening viral
infections. In cancer, the Hemopurifier is designed to deplete the
presence of circulating tumor-derived exosomes that promote immune
suppression.
The Hemopurifier® is an FDA designated "Breakthrough Device"
related to the treatment of individuals with advanced or metastatic
cancer who are either unresponsive to or intolerant of standard of
care therapy, and with cancer types in which exosomes have been
shown to participate in the development or severity of the disease
cancer. Under an Investigational Device Exemption (IDE)
application, in October 2019 the FDA
approved an Early Feasibility Study (EFS), which is the device
equivalent of a Phase 1 clinical trial for a drug or biologic, in a
single center, open label trial in 10 to 12 subjects. The
study is evaluating the HEMOPURIFIER® for reducing
cancer-associated exosomes prior to the administration of
standard-of-care pembrolizumab (KEYTRUDA®), which is a first-line
therapy for patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck. The EFS is being conducted at the
University of Pittsburgh Medical Center
Hillman Cancer Center.
The Hemopurifier also holds a Breakthrough Device designation
related to life-threatening viruses that are not addressed with
approved therapies. In June
2020, the FDA approved an amendment to the Company's
existing open IDE for the Hemopurifier in life threatening viral
infections, to allow for the treatment of patients with
SARS-CoV-2/COVID-19 infection. This will allow for up to 40
of these patients to be treated under a new Early Feasibility Study
protocol at up to 20 clinical sites in the U.S.
Aethlon also owns 80% of Exosome Sciences, Inc., which is
focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially," "appear" or
similar expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. Factors that
may contribute to such differences include, without limitation,
Aethlon Medical, Inc.'s (the Company) ability to enroll patients in
the Early Feasibility Studies, the Company's ability to
successfully complete the Early Feasibility Studies and achieve the
endpoints for the studies, or any future studies with its
Hemopurifier or to successfully develop and commercialize the
Hemopurifier. The foregoing list of risks and uncertainties is
illustrative, but is not exhaustive. Additional factors that could
cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year
ended March 31, 2020, and in the
Company's other filings with the Securities and Exchange
Commission, including its quarterly Reports on Form 10-Q. Except as
may be required by law, the Company does not intend, nor does it
undertake any duty, to update this information to reflect future
events or circumstances.
Company Contact:
Jim
Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Media Contact:
Tony
Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan
Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-bioconnect-2021-conference-301199514.html
SOURCE Aethlon Medical, Inc.